Zimmer Biomet Holdings, Inc. (ZBH) Q3 2024 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants David DeMartino – Senior Vice President-Investor Relations Ivan Tornos – President and Chief Executive Officer Suketu Upadhyay – Chief Financial Officer and Executive Vice President-Finance, Operations and Supply Chain Conference Call Participants Travis Steed – Bank of America Vik Chopra – Wells Fargo David Roman – Goldman Sachs Allen Gong – JPMorgan Matthew O'Brien – Piper Sandler Chris Pasquale – Nephron Steve Lichtman – Oppenheimer Sophia Knopp – Evercore ISI Richard Newitter – Truist Securities Jeff Johnson – Baird Caitlin Cronin – Canaccord Mike Matson – Needham & Company Shagun Singh – RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, October 30, 2024.
Zimmer (ZBH) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Implant maker Zimmer Biomet lowers full-year profit forecast
Hip implant maker Zimmer Biomet lowered its annual profit forecast on Wednesday following last month's disruptions to a software platform that was managing some of the company's operations.
Zimmer Biomet (ZBH) Misses Q3 Earnings Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $1.74 per share, missing the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.65 per share a year ago.
Countdown to Zimmer (ZBH) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Zimmer (ZBH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET.
Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure
In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
